Takeda Pharmaceutical Company Limited filed a Form 6-K with the U.S. Securities and Exchange Commission on October 29, 2026, furnishing an English translation of its Semi-annual Securities Report for the six-month period ended September 30, 2026, as submitted to Japan's Kanto Local Finance Bureau under the Financial Instruments and Exchange Act of Japan.

Key Highlights

  • Revenue: JPY 2,407.0 billion for the six-month period ended September 30, 2026, up JPY 187.5 billion (+8.4% AER, -1.0% CER) compared to the same period of the prior fiscal year.
  • Net profit: JPY 305.7 billion for the period, an increase of JPY 193.2 billion (+171.6% AER, +148.7% CER) versus the prior-year period.
  • Operating profit: JPY 406.7 billion, up JPY 153.2 billion (+60.4% AER, +45.0% CER) year-over-year.
  • Basic earnings per share: JPY 192.53 for the six-month period ended September 30, 2026, compared to JPY 71.57 for the same period ended September 30, 2025.
  • Total assets: JPY 15,271,498 million as of September 30, 2026, versus JPY 15,511,506 million as of March 31, 2026.
  • Cash and cash equivalents: JPY 418,533 million at the end of the period, down from JPY 595,054 million at the end of the prior fiscal year.
  • Group structure: As of September 30, 2026, Takeda consisted of 157 entities, comprising 147 consolidated subsidiaries (including partnerships), 9 associates, and Takeda Pharmaceutical Company Limited itself.

Takeda's Six-Month Financial Results: Revenue Growth Driven by Yen Depreciation

According to the filing, revenue for the six-month period ended September 30, 2026 reached JPY 2,407.0 billion. The company disclosed that "the increase compared to the same period of the previous fiscal year was primarily attributable to foreign exchange impacts from the depreciation of the Japanese yen." On a constant exchange rate (CER) basis, revenue declined 1.0%, contrasting with the 8.4% increase reported under actual exchange rates (AER). Revenue from key business areas - Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, and Neuroscience - totaled JPY 2,308.2 billion, up JPY 191.8 billion (+9.1% AER, -0.5% CER), while revenue outside those areas was JPY 98.8 billion, down JPY 4.3 billion (-4.2% AER, -12.7% CER).

The filing reported profit before tax of JPY 318.7 billion for the period, compared to JPY 178.8 billion in the same period of FY2025, an increase of JPY 139.9 billion (+78.2% AER). Income tax expenses fell sharply to JPY 13.0 billion from JPY 66.3 billion in the prior-year period, contributing to the substantial increase in net profit to JPY 305.7 billion. Net profit attributable to owners of the Company was JPY 305.6 billion. Amortization and impairment losses on intangible assets associated with products declined by JPY 118.3 billion (-35.1% AER), which the filing identifies as a notable line-item change. Operating expenses and research and development expenses rose, with R&D reaching JPY 338.6 billion (+10.9% AER).

Total equity as of September 30, 2026 was JPY 7,417,176 million, compared to JPY 7,430,649 million at March 31, 2026. Net cash from operating activities was JPY 431,890 million, down from JPY 593,651 million in the prior-year period. The filing noted no new risk factors were identified for the six-month period and no significant changes relative to the Annual Securities Report for the year ended March 31, 2026. The report was signed by Norimasa Takeda, Chief Accounting Officer and Corporate Controller, on behalf of the registrant.

What Was Disclosed

Takeda filed its Semi-annual Securities Report covering April 1 to September 30, 2026, reporting JPY 2,407.0 billion in revenue and JPY 305.7 billion in net profit for the period, along with condensed interim consolidated financial statements prepared under IAS 34.